Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease

Phuong L. Nguyen, Nancy L. Harris, Jerome Ritz, Michael J. Robertson

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

CD95 (APO-1/Fas) is a member of the superfamily that includes the nerve growth factor and tumor necrosis factor receptors, OX40, CD27, CD30, and CD40. Present on a minority of resting blood lymphocytes, CD95 expression is upregulated on activated T and B lymphocytes and natural killer cells, where binding of the antigen by anti-Fas and anti-APO-1 antibodies has been shown to induce apoptosis. This CD95-mediated apoptosis is at least partially inhibited by expression of the Bcl-2 protooncogene. To evaluate possible roles of CD95 and Bcl-2 in growth regulation of lymphoid neoplasms, we studied by immunohistochemistry the expression of CD95 and Bcl-2 in 67 B- and 5 T-cell lympbomas, and 10 cases of Hodgkin's disease. In all, 29 B and. 2 T cell lymphomas, and 9 cases of Hodgkin's disease expressed CD95. Compared with diffuse large B-cell and Burkitt-like lymphomas, low-grade B-cell lymphomas more frequently expressed CD95 (52% versus 26%; P > .005). None of the B-cell small lymphocytic lymphomas or mantle cell lymphomas expressed CD95, whereas the majority of follicle center lymphomas, extranodal marginal zone B-cell lymphomas, and immunocytomas were CD95+. Of the 29 CD95+ B-cell lymphomas, only 33% of the high-grade group coexpressed Bcl-2, compared with 87% of the low-grade group (TP < .04). Two of three peripheral T-cell lymphomas - including one anaplastic large cell lymphoma-expressed CD95. Staining for CD95 was seen in 9 of 10 cases of Hodgkin's disease. The infrequent expression of CD95 in high-grade B-cell lymphomas suggests an association between loss ofCD95 expression/function and a more aggressive tumor grade. Whereas frequent coexpression of Bcl-2 with CD95 may protect low-grade B-cell lymphomas against CD95-mediated apoptosis, in the high-grade group such coexpression is infrequent, and other regulators besides Bcl-2 may be involved in modulating the apoptosis signal delivered by CD95.

Original languageEnglish (US)
Pages (from-to)847-853
Number of pages7
JournalAmerican Journal of Pathology
Volume148
Issue number3
StatePublished - Mar 1996
Externally publishedYes

Fingerprint

CD95 Antigens
B-Cell Lymphoma
Hodgkin Disease
Non-Hodgkin's Lymphoma
Apoptosis
B-Lymphocytes
Proteins
Peripheral T-Cell Lymphoma
Anaplastic Large-Cell Lymphoma
T-Lymphocytes
Mantle-Cell Lymphoma
Marginal Zone B-Cell Lymphoma
Burkitt Lymphoma
T-Cell Lymphoma
Tumor Necrosis Factor Receptors
Nerve Growth Factor
B-Cell Chronic Lymphocytic Leukemia
Natural Killer Cells
Lymphoma
Neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Nguyen, P. L., Harris, N. L., Ritz, J., & Robertson, M. J. (1996). Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. American Journal of Pathology, 148(3), 847-853.

Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. / Nguyen, Phuong L.; Harris, Nancy L.; Ritz, Jerome; Robertson, Michael J.

In: American Journal of Pathology, Vol. 148, No. 3, 03.1996, p. 847-853.

Research output: Contribution to journalArticle

Nguyen, PL, Harris, NL, Ritz, J & Robertson, MJ 1996, 'Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease', American Journal of Pathology, vol. 148, no. 3, pp. 847-853.
Nguyen, Phuong L. ; Harris, Nancy L. ; Ritz, Jerome ; Robertson, Michael J. / Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. In: American Journal of Pathology. 1996 ; Vol. 148, No. 3. pp. 847-853.
@article{c117d8aed6ee4aae8e3e867451034184,
title = "Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease",
abstract = "CD95 (APO-1/Fas) is a member of the superfamily that includes the nerve growth factor and tumor necrosis factor receptors, OX40, CD27, CD30, and CD40. Present on a minority of resting blood lymphocytes, CD95 expression is upregulated on activated T and B lymphocytes and natural killer cells, where binding of the antigen by anti-Fas and anti-APO-1 antibodies has been shown to induce apoptosis. This CD95-mediated apoptosis is at least partially inhibited by expression of the Bcl-2 protooncogene. To evaluate possible roles of CD95 and Bcl-2 in growth regulation of lymphoid neoplasms, we studied by immunohistochemistry the expression of CD95 and Bcl-2 in 67 B- and 5 T-cell lympbomas, and 10 cases of Hodgkin's disease. In all, 29 B and. 2 T cell lymphomas, and 9 cases of Hodgkin's disease expressed CD95. Compared with diffuse large B-cell and Burkitt-like lymphomas, low-grade B-cell lymphomas more frequently expressed CD95 (52{\%} versus 26{\%}; P > .005). None of the B-cell small lymphocytic lymphomas or mantle cell lymphomas expressed CD95, whereas the majority of follicle center lymphomas, extranodal marginal zone B-cell lymphomas, and immunocytomas were CD95+. Of the 29 CD95+ B-cell lymphomas, only 33{\%} of the high-grade group coexpressed Bcl-2, compared with 87{\%} of the low-grade group (TP < .04). Two of three peripheral T-cell lymphomas - including one anaplastic large cell lymphoma-expressed CD95. Staining for CD95 was seen in 9 of 10 cases of Hodgkin's disease. The infrequent expression of CD95 in high-grade B-cell lymphomas suggests an association between loss ofCD95 expression/function and a more aggressive tumor grade. Whereas frequent coexpression of Bcl-2 with CD95 may protect low-grade B-cell lymphomas against CD95-mediated apoptosis, in the high-grade group such coexpression is infrequent, and other regulators besides Bcl-2 may be involved in modulating the apoptosis signal delivered by CD95.",
author = "Nguyen, {Phuong L.} and Harris, {Nancy L.} and Jerome Ritz and Robertson, {Michael J.}",
year = "1996",
month = "3",
language = "English (US)",
volume = "148",
pages = "847--853",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease

AU - Nguyen, Phuong L.

AU - Harris, Nancy L.

AU - Ritz, Jerome

AU - Robertson, Michael J.

PY - 1996/3

Y1 - 1996/3

N2 - CD95 (APO-1/Fas) is a member of the superfamily that includes the nerve growth factor and tumor necrosis factor receptors, OX40, CD27, CD30, and CD40. Present on a minority of resting blood lymphocytes, CD95 expression is upregulated on activated T and B lymphocytes and natural killer cells, where binding of the antigen by anti-Fas and anti-APO-1 antibodies has been shown to induce apoptosis. This CD95-mediated apoptosis is at least partially inhibited by expression of the Bcl-2 protooncogene. To evaluate possible roles of CD95 and Bcl-2 in growth regulation of lymphoid neoplasms, we studied by immunohistochemistry the expression of CD95 and Bcl-2 in 67 B- and 5 T-cell lympbomas, and 10 cases of Hodgkin's disease. In all, 29 B and. 2 T cell lymphomas, and 9 cases of Hodgkin's disease expressed CD95. Compared with diffuse large B-cell and Burkitt-like lymphomas, low-grade B-cell lymphomas more frequently expressed CD95 (52% versus 26%; P > .005). None of the B-cell small lymphocytic lymphomas or mantle cell lymphomas expressed CD95, whereas the majority of follicle center lymphomas, extranodal marginal zone B-cell lymphomas, and immunocytomas were CD95+. Of the 29 CD95+ B-cell lymphomas, only 33% of the high-grade group coexpressed Bcl-2, compared with 87% of the low-grade group (TP < .04). Two of three peripheral T-cell lymphomas - including one anaplastic large cell lymphoma-expressed CD95. Staining for CD95 was seen in 9 of 10 cases of Hodgkin's disease. The infrequent expression of CD95 in high-grade B-cell lymphomas suggests an association between loss ofCD95 expression/function and a more aggressive tumor grade. Whereas frequent coexpression of Bcl-2 with CD95 may protect low-grade B-cell lymphomas against CD95-mediated apoptosis, in the high-grade group such coexpression is infrequent, and other regulators besides Bcl-2 may be involved in modulating the apoptosis signal delivered by CD95.

AB - CD95 (APO-1/Fas) is a member of the superfamily that includes the nerve growth factor and tumor necrosis factor receptors, OX40, CD27, CD30, and CD40. Present on a minority of resting blood lymphocytes, CD95 expression is upregulated on activated T and B lymphocytes and natural killer cells, where binding of the antigen by anti-Fas and anti-APO-1 antibodies has been shown to induce apoptosis. This CD95-mediated apoptosis is at least partially inhibited by expression of the Bcl-2 protooncogene. To evaluate possible roles of CD95 and Bcl-2 in growth regulation of lymphoid neoplasms, we studied by immunohistochemistry the expression of CD95 and Bcl-2 in 67 B- and 5 T-cell lympbomas, and 10 cases of Hodgkin's disease. In all, 29 B and. 2 T cell lymphomas, and 9 cases of Hodgkin's disease expressed CD95. Compared with diffuse large B-cell and Burkitt-like lymphomas, low-grade B-cell lymphomas more frequently expressed CD95 (52% versus 26%; P > .005). None of the B-cell small lymphocytic lymphomas or mantle cell lymphomas expressed CD95, whereas the majority of follicle center lymphomas, extranodal marginal zone B-cell lymphomas, and immunocytomas were CD95+. Of the 29 CD95+ B-cell lymphomas, only 33% of the high-grade group coexpressed Bcl-2, compared with 87% of the low-grade group (TP < .04). Two of three peripheral T-cell lymphomas - including one anaplastic large cell lymphoma-expressed CD95. Staining for CD95 was seen in 9 of 10 cases of Hodgkin's disease. The infrequent expression of CD95 in high-grade B-cell lymphomas suggests an association between loss ofCD95 expression/function and a more aggressive tumor grade. Whereas frequent coexpression of Bcl-2 with CD95 may protect low-grade B-cell lymphomas against CD95-mediated apoptosis, in the high-grade group such coexpression is infrequent, and other regulators besides Bcl-2 may be involved in modulating the apoptosis signal delivered by CD95.

UR - http://www.scopus.com/inward/record.url?scp=0030091222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030091222&partnerID=8YFLogxK

M3 - Article

C2 - 8774139

AN - SCOPUS:0030091222

VL - 148

SP - 847

EP - 853

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -